In February 2017, the US Food and Drug Administration approved injectable brodalumab (210 mg) to treat patients with moderate to severe plaque psoriasis. In clinical trials, brodalumab treatment showed a rapid response, both for clearing patient's psoriasis and helping patients feel better. Dr. Lawrence Green reviews the efficacy and safety data in this video. He also explains the REMS (Risk Evaluation and Mitigation Strategy) program, which was developed because of the observed suicidal behavior in participants treated with brodalumab.